|
The role of statins in Alzheimer's disease
|
Elham Hadipour   , Zahra Tayarani Najjaran , Masoud Fereidoni * |
| Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran |
|
|
Abstract: (2620 Views) |
Background and aim: Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by severe cognitive impairment, inability to perform activities of daily living and mood changes. An increasing number of studies have supported that high cholesterol is a risk factor for the pathogenesis of AD, including beta-amyloid peptides (Aβ) pathology. Clinical and biomolecular studies have shown that statins, cholesterol-lowering drugs, could stave off the symptoms of AD. The role of cholesterol in the process of Aβ production and deposition has been fully considered on the basis of scientific results during the last 2 decades. It is clear that statins play a neuroprotective role to limit beta-amyloid pathology via cholesterol-lowering therapies. In addition, statins may favor the α-secretase nonamyloidogenic pathway of APP processing and inhibit the dimerization of b-secretase. Statins retard Aβ pathology via the anti-inflammation, anti-atherosclerotic actions, anti-oxidant and anti-apoptotic effects. There are a number of individual clinical cases where cognition is clearly adversely affected by statins. Also these findings suggest that administration of statins in midlife might prevent AD in late life by modifying genetic and non-genetic risk factors for AD.
Results and Conclusion: It appears that there is still a lot of work to implement statin medications in clinical and preclinical studies of AD.
|
|
| Keywords: Alzheimer's disease, Beta-amyloid peptides, Statin |
|
|
Full-Text [PDF 1261 kb]
(3012 Downloads)
|
|
Type of Study: Original Research |
Subject:
Neuroscience
|
|
|
|
|
|
|
| Add your comments about this article |
|
|
|
